In these aggressive tumors, E-cadherin was highly expressed in both primary lesions and intralymphatic tumor emboli, thus challenging the common notion that E-cadherin loss correlates with poor prognosis in carcinomas. This evidence concerns the gene CDH1 and neoplasm.